World's Best Scientists 2026 revealed!
Michel Attal

Michel Attal

D-Index & Metrics

Medicine

D-Index
117
Citations
58961
World Ranking
4164
National Ranking
42

Overview

Michel Attal is affiliated with Janssen (Belgium) in Belgium, contributing to research primarily in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their work focuses largely on Hematology, Molecular Biology, and Oncology, with emphasis on subfields such as Genetics and Radiology, Nuclear Medicine and Imaging.

The research topics most frequently addressed by Michel Attal include:

  • Multiple Myeloma Research and Treatments
  • Cancer Treatment and Pharmacology
  • Protein Degradation and Inhibitors
  • Histone Deacetylase Inhibitors Research
  • Peptidase Inhibition and Analysis
  • Monoclonal and Polyclonal Antibodies Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment

Michel Attal has published extensively in various venues, with frequent publications in:

  • Blood
  • Journal of Clinical Oncology
  • Haematologica
  • British Journal of Haematology
  • New England Journal of Medicine

Frequent coauthors collaborating with Michel Attal include:

  • Philippe Moreau
  • Hervé Avet-Loiseau
  • Thierry Façon
  • Aurore Perrot
  • Xavier Leleu

Among their recent papers are:

  • Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma, 2022, New England Journal of Medicine
  • Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma, 2020, Journal of Clinical Oncology
  • Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial, 2020, Blood
  • Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma, 2020, Blood Cancer Journal
  • Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma, 2020, Leukemia & lymphoma/Leukemia and lymphoma

Their academic output demonstrates a concentrated focus on multiple myeloma and related therapeutic strategies, continuously contributing to advances in hematological cancer treatment through clinical research and follow-up studies.

Best Publications

  • A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

    Michel Attal;Jean-Luc Harousseau;Anne-Marie Stoppa;Jean-Jacques Sotto

  • International uniform response criteria for multiple myeloma

    B. G. M. Durie;J.-L. Harousseau;J. S. Miguel;J. Blade

  • Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst

  • Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma

    Michel Attal;Jean-Luc Harousseau;Thierry Facon;François Guilhot

  • Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

    Michel Attal;Valerie Lauwers-Cances;Gerald Marit;Denis Caillot

  • Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.

    Thierry Facon;Jean Yves Mary;Cyrille Hulin;Lotfi Benboubker

  • Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

    Michel Attal;Valerie Lauwers-Cances;Cyrille Hulin;Xavier Leleu

  • Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome

    Hervé Avet-Loiseau;Michel Attal;Philippe Moreau;Catherine Charbonnel

  • International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

    A. Dispenzieri;R. Kyle;G. Merlini;J. S. Miguel

  • Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

    Niccolo Bolli;Hervé Avet-Loiseau;David C. Wedge;Peter Van Loo

  • Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

    Philippe Moreau;Michel Attal;Cyrille Hulin;Bertrand Arnulf

  • Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

    Pieter Sonneveld;Hervé Avet-Loiseau;Sagar Lonial;Saad Usmani

  • Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

    Lotfi Benboubker;Meletios Athanasios Dimopoulos;Angela Dispenzieri;John Catalano

  • Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

    Michel Attal;Jean-Luc Harousseau;Serge Leyvraz;Chantal Doyen

  • Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

    Thierry Facon;Shaji Kumar;Torben Plesner;Robert Z Orlowski

  • Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

    P. Moreau;J. San Miguel;P. Sonneveld;M. V. Mateos

  • Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial

    Philippe Moreau;Thierry Facon;Michel Attal;Cyrille Hulin

  • Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

    Jean-Luc Harousseau;Michel Attal;Hervé Avet-Loiseau;Gerald Marit

  • Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.

    Philip L. McCarthy;Sarah A. Holstein;Maria Teresa Petrucci;Paul G. Richardson

  • Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Commentary

    Giampaolo Merlini;Michel Attal;Jean-Luc Harousseau;Serge Leyvraz

Frequent Co-Authors

Thierry Facon
Thierry Facon Centre Hospitalier Régional et Universitaire de Lille
Philippe Moreau
Philippe Moreau University of Nantes
Denis Caillot
Denis Caillot Grenoble Alpes University
Jean-Luc Harousseau
Jean-Luc Harousseau University of Nantes
Xavier Leleu
Xavier Leleu Harvard University
Paul G. Richardson
Paul G. Richardson Harvard University
Nikhil C. Munshi
Nikhil C. Munshi Harvard University
Mauricette Michallet
Mauricette Michallet University of Helsinki
Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the USA offers a wide spectrum of online degree options and flexible learning pathways. For those interested in leadership roles in hospitals or clinics, an healthcare administration accelerated degree can fast-track your entry into healthcare management. These programs are designed for busy professionals seeking to grow into leadership positions quickly.

Registered nurses aiming to advance their careers can consider specialized RN to NP bridge programs, which enable RNs to become nurse practitioners through online study options. Nutrition is another growing field; earning an online degree nutrition can open doors to roles in clinical practice, wellness coaching, and community health.

It’s essential to choose programs with proper accreditation to ensure educational quality. If you’re exploring which online healthcare degree programs are recognized for their accreditation by CAHME, check out reputable schools that meet these standards for Master of Health Administration (MHA) degrees. Your choice of program will impact both your career prospects and eligibility for future licensing or certification.

Best Scientists Citing Michel Attal

Trending Scientists

Recently Published Articles